Literature DB >> 32212356

Noninvasive Prediction of High-Grade Prostate Cancer via Biparametric MRI Radiomics.

Lixin Gong1,2, Min Xu3, Mengjie Fang2,4, Jian Zou5, Shudong Yang6, Xinyi Yu3, Dandan Xu3, Lijuan Zhou3, Hailin Li2, Bingxi He2,4, Yan Wang3, Xiangming Fang3, Di Dong2,4, Jie Tian1,2,7.   

Abstract

BACKGROUND: Gleason score (GS) is a histologic prognostic factor and the basis of treatment decision-making for prostate cancer (PCa). Treatment regimens between lower-grade (GS ≤7) and high-grade (GS >7) PCa differ largely and have great effects on cancer progression.
PURPOSE: To investigate the use of different sequences in biparametric MRI (bpMRI) of the prostate gland for noninvasively distinguishing high-grade PCa. STUDY TYPE: Retrospective. POPULATION: In all, 489 patients (training cohort: N = 326; test cohort: N = 163) with PCa between June 2008 and January 2018. FIELD STRENGTH/SEQUENCE: 3.0T, pelvic phased-array coils, bpMRI including T2 -weighted imaging (T2 WI) and diffusion-weighted imaging (DWI); apparent diffusion coefficient map extracted from DWI. ASSESSMENT: The whole prostate gland was delineated. Radiomic features were extracted and selected using the Kruskal-Wallis test, the minimum redundancy-maximum relevance, and the sequential backward elimination algorithm. Two single-sequence radiomic (T2 WI, DWI) and two combined (T2 WI-DWI, T2 WI-DWI-Clinic) models were respectively constructed and validated via logistic regression. STATISTICAL TESTS: The Kruskal-Wallis test and chi-squared test were utilized to evaluate the differences among variable groups. P < 0.05 determined statistical significance. The area under the receiver operating characteristic curve (AUC), specificity, sensitivity, and accuracy were used to evaluate model performance. The Delong test was conducted to compare the differences between the AUCs of all models. RESULT: All radiomic models showed significant (P < 0.001) predictive performances. Between the single-sequence radiomic models, the DWI model achieved the most encouraging results, with AUCs of 0.801 and 0.787 in the training and test cohorts, respectively. For the combined models, the T2 WI-DWI models acquired an AUC of 0.788, which was almost the same with DWI in the test cohort, and no significant difference was found between them (training cohort: P = 0.199; test cohort: P = 0.924). DATA
CONCLUSION: Radiomics based on bpMRI can noninvasively identify high-grade PCa before the operation, which is helpful for individualized diagnosis of PCa. LEVEL OF EVIDENCE: 4 TECHNICAL EFFICACY STAGE: 2 J. Magn. Reson. Imaging 2020;52:1102-1109.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  Gleason score; biparametric MRI; prostate cancer; radiomics

Mesh:

Year:  2020        PMID: 32212356     DOI: 10.1002/jmri.27132

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  10 in total

Review 1.  The role of radiomics in prostate cancer radiotherapy.

Authors:  Rodrigo Delgadillo; John C Ford; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Strahlenther Onkol       Date:  2020-08-21       Impact factor: 3.621

Review 2.  Overview of radiomics in prostate imaging and future directions.

Authors:  Hwan-Ho Cho; Chan Kyo Kim; Hyunjin Park
Journal:  Br J Radiol       Date:  2021-11-29       Impact factor: 3.039

Review 3.  Challenges in ensuring the generalizability of image quantitation methods for MRI.

Authors:  Kathryn E Keenan; Jana G Delfino; Kalina V Jordanova; Megan E Poorman; Prathyush Chirra; Akshay S Chaudhari; Bettina Baessler; Jessica Winfield; Satish E Viswanath; Nandita M deSouza
Journal:  Med Phys       Date:  2021-09-29       Impact factor: 4.506

4.  Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion.

Authors:  Ling Yang; Zhengyan Li; Xu Liang; Jingxu Xu; Yusen Cai; Chencui Huang; Mengni Zhang; Jin Yao; Bin Song
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

5.  Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68 Ga-PSMA-11 PET/CT in patients with primary prostate cancer.

Authors:  Zhilong Yi; Siqi Hu; Xiaofeng Lin; Qiong Zou; MinHong Zou; Zhanlei Zhang; Lei Xu; Ningyi Jiang; Yong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-30       Impact factor: 10.057

6.  Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.

Authors:  Valentina Brancato; Marco Aiello; Luca Basso; Serena Monti; Luigi Palumbo; Giuseppe Di Costanzo; Marco Salvatore; Alfonso Ragozzino; Carlo Cavaliere
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

7.  Editorial: Radiomics Advances Precision Medicine.

Authors:  Bo Gao; Di Dong; Huimao Zhang; Zaiyi Liu; Seyedmehdi Payabvash; Bihong T Chen
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

Review 8.  Current Value of Biparametric Prostate MRI with Machine-Learning or Deep-Learning in the Detection, Grading, and Characterization of Prostate Cancer: A Systematic Review.

Authors:  Henrik J Michaely; Giacomo Aringhieri; Dania Cioni; Emanuele Neri
Journal:  Diagnostics (Basel)       Date:  2022-03-24

Review 9.  Radiomics in prostate cancer: an up-to-date review.

Authors:  Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru
Journal:  Ther Adv Urol       Date:  2022-07-04

Review 10.  Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies.

Authors:  Simon K B Spohn; Alisa S Bettermann; Fabian Bamberg; Matthias Benndorf; Michael Mix; Nils H Nicolay; Tobias Fechter; Tobias Hölscher; Radu Grosu; Arturo Chiti; Anca L Grosu; Constantinos Zamboglou
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.